Core Viewpoint - Jupiter Neurosciences, Inc. has announced the addition of Chris Webber as the second brand ambassador for its new longevity supplement line, Nugevia™, which is based on clinical science and innovative performance-driven technology [1][3]. Company Overview - Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on addressing neuroinflammation and promoting healthy aging through a dual-path strategy that includes advancing therapeutics for CNS disorders and entering the consumer longevity market with Nugevia™ [7]. - The company’s proprietary JOTROL™ platform enhances the bioavailability of resveratrol, which is the foundation for both its therapeutic pipeline and the Nugevia™ product line [10]. Product Details - Nugevia™ features three initial formulations—GLO, MND, and PWR—designed to support cellular resilience through synergistic ingredients optimized for absorption via the JOTROL™ system [4]. - The Nugevia™ brand aims to tap into the rapidly growing longevity market, projected to reach $8 trillion by 2030, creating a revenue stream to support ongoing clinical development and enhance long-term shareholder value [5][6]. Scientific Validation - JOTROL™ has demonstrated over nine times higher bioavailability compared to traditional resveratrol products, as evidenced by a Phase I study published in reputable journals [9]. - The technology aims to provide pharmaceutical-grade bioavailability in the wellness space, targeting cognitive health, skin vitality, and cellular energy [10].

Core Insights - Jupiter Neurosciences, Inc. is advancing its proprietary resveratrol-based platform, JOTROL, which offers significant advantages over traditional resveratrol formulations [1][3][10] - JOTROL has demonstrated a nine-fold increase in bioavailability compared to conventional resveratrol, while avoiding gastrointestinal side effects [3][7][10] - The company is progressing JOTROL towards a Phase IIa trial for Parkinson's Disease, supported by promising preclinical data [4][8][10] Scientific and Clinical Advantages - Resveratrol is known for its antioxidant, mitochondrial, and anti-inflammatory properties, but its therapeutic use has been limited due to poor bioavailability and GI side effects [2][9] - JOTROL promotes mitochondrial biogenesis and reduces neuroinflammation, addressing key factors in neurodegenerative diseases and aging [5][6] Product Development and Market Strategy - JOTROL is not only aimed at pharmaceutical applications but also serves as the foundation for the Nugevia consumer product line, targeting cognitive health, mitochondrial energy, and skin vitality [4][11] - The Nugevia product line is set to launch in Q3 2025, leveraging the same delivery technology as JOTROL to provide clinical-grade bioavailability in the wellness market [11] Intellectual Property and Market Potential - The company has secured intellectual property rights for JOTROL in major markets including the U.S., EU, China, Japan, and Hong Kong, valid through 2036 [7] - JOTROL's ability to cross the blood-brain barrier positions it as a potential treatment for CNS disorders such as Parkinson's and Alzheimer's [7][8]